PMID- 36872054
OWN - NLM
STAT- MEDLINE
DCOM- 20230307
LR  - 20230325
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 26
IP  - 2
DP  - 2023 Feb 20
TI  - [Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced 
      NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature 
      Review].
PG  - 158-164
LID - 10.3779/j.issn.1009-3419.2023.101.04 [doi]
AB  - With the development of sequencing technology, the detection rate of non-small 
      cell lung cancer (NSCLC) with primary epidermal growth factor receptor (EGFR) 
      T790M mutation is increasing. However, the first-line treatment for primary EGFR 
      T790M-mutated NSCLC still lacks standard recommendations. Here, we reported three 
      advanced NSCLC cases with EGFR-activating mutation and primary T790M mutation. 
      The patients were initially treated with Aumolertinib combination with 
      Bevacizumab; among which, one case was discontinued Bevacizumab due to bleeding 
      risk after treatment for three months. Treatment was switched to Osimertinib 
      after ten months of treatment. Another case switched to Osimertinib and 
      discontinued Bevacizumab after thirteen months of treatment. The best effect 
      response in all three cases was partial response (PR) after initial treatment. 
      Two cases progressed after first-line treatment and progression-free survival 
      (PFS) was eleven months and seven months respectively. The other one patient had 
      persistent response after treatment, and the treatment duration has reached 
      nineteen months. Two cases had multiple brain metastases before administration 
      and the best response to intracranial lesions was PR. The intracranial PFS was 
      fourteen months and not reached (16+ months), respectively. There were no new 
      adverse events (AEs), and no AEs of grade three or above were reported. In 
      addition, we summarized the research progress of Osimertinib in the treatment of 
      NSCLC with primary EGFR T790M mutation. In conclusion, Aumolertinib combined with 
      Bevacizumab in the treatment of advanced NSCLC with primary EGFR T790M mutation 
      has a high objective response rate (ORR) and control ability of intracranial 
      lesions, which can be used as one of the initial options for first-line advanced 
      NSCLC with primary EGFR T790M mutation.
.
FAU - Yang, Xue
AU  - Yang X
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Meng, Fanlu
AU  - Meng F
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Zhong, Diansheng
AU  - Zhong D
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
LA  - chi
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 3C06JJ0Z2O (osimertinib)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - T4RS462G19 (aumolertinib)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - Bevacizumab
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - ErbB Receptors
MH  - *Lung Neoplasms
MH  - Mutation
MH  - Protein Kinase Inhibitors
PMC - PMC10033243
OTO - NOTNLM
OT  - Aumolertinib
OT  - Bevacizumab
OT  - Lung neoplasms
OT  - Primary T790M
EDAT- 2023/03/06 06:00
MHDA- 2023/03/08 06:00
PMCR- 2023/02/20
CRDT- 2023/03/05 21:12
PHST- 2023/03/05 21:12 [entrez]
PHST- 2023/03/06 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
PHST- 2023/02/20 00:00 [pmc-release]
AID - 10.3779/j.issn.1009-3419.2023.101.04 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2023 Feb 20;26(2):158-164. doi: 
      10.3779/j.issn.1009-3419.2023.101.04.